Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q2 2023 call → NOWe need to determine if management conveys that outsiders are currently underweighting something the company has already done, and whether they point to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Key points from management: - Brian McKelligon: "Akoya had a very strong second quarter of 2023, highlighted by record revenue of $23.5 million, a 31% growth over the prior year and record system placements of 72 in the quarter. Our cumulative installed base is now 1,064 spatial biology instruments, the largest in the industry." - They discuss their strategy: "The second phase of our strategy initiated beginning of this year, targets improving operational leverage, while continuing to deliver sustained topline growth, with a focus on system placement expansion and especially, driving increased reagent revenue." - They mention new product launches: Fusion 2.0 upgrade, PhenoCode reagent panels, etc. - They talk about the installed base and reagent pull-through. Johnny Ek: "In the first half of 2023, we are seeing encouraging results of our emphasis on driving reagent growth. The annualized second quarter reagent pull-through has now increased to the mid-$30,000 range for both the PhenoCycler and HT... This is compared to an annualized pull-through per instrument in 2022 in the low $30,000 range." - They mention the CLIA Lab, CRO network, partnerships with Agilent, AstraZeneca, Acrivon. - They discuss gross margin and a one-time charge. - They reiterate guidance. Now, does management convey that outsiders are currently underweighting something the company has already done? Look for statements about how the company is perceived, valued, measured, modeled, or asked about. There is a mention of "we're making targeted investments in our business to drive strong revenue growth, while streamlining our cost structure as we move the business towards profitability." That's not about perception. There is a mention of "we have over 1,000 publications" and "the transformative power of Akoya solutions has been validated by our customers." That's not about underweighting. There is a mention of "we continue to see robust growth in the translational markets with growing momentum within our biopharma and CRO partners." That's not about perception.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.